Bu-zhong-yi-qi decoction regulates JNK/c-JUN signaling pathway to improve skeletal muscle atrophy caused by cancer cachexia

作者：Jia Li, Ying Zhang, Zhe Su, Tingting He, Ze Chen, Zhiwei Pan, Chao Ding, Zhichao Yu, Lei Bi · 发表于：Journal of Ethnopharmacology · 年份：2025 · DOI：10.1016/j.jep.2025.120078 · 被引用次数：4 · 研究领域：Muscle Physiology and Disorders、Nutrition and Health in Aging、Metabolism, Diabetes, and Cancer

ETHNOPHARMACOLOGICAL RELEVANCE: With a prevalence reaching 80 % in terminal cancer patients, cancer cachexia (CC) manifests as irreversible skeletal muscle wasting. Presently, there exists no effective therapeutic strategy for managing cancer cachexia. Traditional Chinese medicine (TCM) contributes significantly to the management of CC, enhancing quality of life and potentially prolonging survival in affected patients. Bu-zhong-yi-qi decoction (BYD), a classical Chinese formulation, demonstrates therapeutic potential for tumor-associated conditions and muscle-related disorders. However, its precise pharmacological mechanisms remain to be fully elucidated. AIM OF THE STUDY: This study aims to systematically investigate the therapeutic effects and underlying mechanisms of BYD on muscle atrophy caused by CC through an integrated approach combining network pharmacology analysis with comprehensive in vivo and in vitro experimental validation. MATERIALS AND METHODS: Network pharmacology analysis was employed to recognize bioactive components, potential therapeutic targets, and associated pathways of BYD. Molecular docking simulations were subsequently performed to evaluate the binding affinity between BYD constituents and key target proteins. The skeletal muscle atrophy model of CC in vivo was established by subcutaneous injection of Lewis lung cancer (LLC) cells. The therapeutic efficacy of BYD was systematically evaluated through a comprehensive assessment of multiple parameters,...